Ichnos Glenmark Innovation Unveils ISB 2301, a Multispecific Antibody Candidate for Solid Tumors
Ichnos Glenmark Innovation, Inc. (IGI), a global clinical-stage biotechnology company, has announced a new development candidate, ISB 2301. The molecule is described as a first-in-class, multispecific immune cells activator designed for the potential treatment of multiple solid tumor indications.ISB 2301 is a next-generation multispecific antibody engineered to target three tumor-associated antigens (TAAs). The drug’s mechanism involves engaging both T cells and Natural Killer (NK) cells, aiming to ignite the immune system and trigger tumor cell death.
The therapeutic design of ISB 2301 is rooted in IGI's proprietary BEAT® platform, which enabled the development of this highly complex multispecific antibody.
***
Key Features of ISB 2301:
| Feature | Description |
|---|---|
| Target Profile | Three tumor-associated antigens (TAAs) |
| Mechanism | Multispecific activation of T cells and NK cells |
| Action | Induces potent antibody-dependent cellular cytotoxicity (ADCC) and potent checkpoint inhibition |
| Immune Response | Sustained type 1 immune response |
***
The company stated that ISB 2301 was engineered to match the biological complexity of solid tumors in a way that conventional immunotherapies have not been able to address. Lida Pacaud, M.D., President and Chief Executive Officer (CEO) of IGI, noted that by simultaneously targeting three TAAs and engaging both T cells and NK cells, the molecule deploys a high level of "multimechanistic precision" setting a new benchmark for multispecific antibodies in solid tumors.
In pre-clinical evaluations, ISB 2301 has demonstrated excellent pharmacokinetics, tolerability, and a favorable safety profile in non-human primates.
IGI announced its plans to advance ISB 2301 toward the clinic, with intentions to submit an Investigational New Drug (IND) application by the end of the current year. The company expects to begin clinical studies with this novel therapeutic approach in 2027.
The firm also highlighted the success of its prior asset, ISB 2001, whose early-stage clinical success led to a collaboration with AbbVie. Pacaud emphasized that the same BEAT® platform provided the necessary engineering capability to develop the complex molecule, ISB 2301.
GLENMARK Stock Price Movement
Glenmark Pharmaceuticals Limited shares today slipped by 1.49% to settle at ₹2379, shedding ₹35.90 from its previous close. The stock found support on a notable volume of 973,567 shares traded during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.